Britannia Pharmaceuticals (part of the STADA Arzneimittel group of companies) has appointed Robert Wood as Marketing Director, for international markets.    

Robert was  previously Director Partners, EMEA at Britannia and as part of the company’s  expansion takes up the new position of Marketing Director with immediate  effect.

Robert has 15 years experience in  the life science and pharmaceutical industries and prior to joining Britannia  in early 2011, began his career at Johnson & Johnson Neurosurgical.  He has also held the position of Business  Unit Director, Pharmaceuticals at International SOS and Vice President of  Business Development at Optasia Medical. Robert  holds an MBA from Kingston Business School, London and a BSc (Hons) in  Biology/Biochemistry from Royal Holloway, University of London. 

‘I am delighted to be continuing to work with Britannia  Pharmaceuticals in this new global role, particularly at this incredibly  interesting time for the APO-go therapy. The initiation of clinical trials to  increase the evidence base for both motor and non-motor effects of APO-go in  Parkinson’s disease and the development of new delivery devices, mean APO-go  will provide an excellent treatment option for many more people with  Parkinson’s.’

Britannia  Pharmaceuticals has been working in the field of Parkinson’s disease (PD) for  over thirty years.  Its APO-go product  range for PD is licensed in almost 40 countries globally.